INTRODUCTION
============

Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in neurodevelopment, neuroprotection, synapse regulation, and learning and memory.[@b1-cpn-14-109]--[@b4-cpn-14-109] BDNF interacts with dopamine, glutamine, and other neurotransmitter systems.[@b1-cpn-14-109],[@b5-cpn-14-109] Because of those interactions, BDNF has also been proposed as an illness and prognostic marker for several neurologic, mental, and addictive disorders.[@b2-cpn-14-109]--[@b4-cpn-14-109],[@b6-cpn-14-109],[@b7-cpn-14-109] Many studies have indicated a correlation between schizophrenia and psychotic episodes with decreased BDNF levels (including two meta-analyses)[@b1-cpn-14-109],[@b8-cpn-14-109]--[@b11-cpn-14-109]; this relationship is probably mediated by alterations in synaptic function and connectivity.[@b9-cpn-14-109] It is known that BDNF is decreased during a patient's first psychotic episode;[@b10-cpn-14-109],[@b11-cpn-14-109] this decrease becomes more marked with disease progression.[@b8-cpn-14-109] Additionally, an age-related reduction in BDNF has been observed in blood.[@b9-cpn-14-109] Antipsychotics and antidepressants can affect BDNF levels; however, findings regarding the effects of antipsychotics are equivocal. Some investigations showed that BDNF levels differed following treatment with typical versus atypical antipsychotics.[@b2-cpn-14-109] Evidence suggests that typical anti-psychotics decrease BDNF levels, but mixed results have been found regarding atypical antipsychotics.[@b2-cpn-14-109]

BDNF has recently been associated with cocaine-induced psychosis (CIP). The term CIP is used to describe symptoms of psychosis (suspiciousness, paranoia, delusions, and hallucinations) that are precipitated by cocaine use.[@b5-cpn-14-109],[@b12-cpn-14-109] For this reason, BDNF levels could act as a biological marker of psychosis in patients with cocaine dependence. Psychotic symptoms have been reported in more than 50% of patients with cocaine dependence; this percentage ranges from 48% to 88% depending on the study variables.[@b13-cpn-14-109]

Numerous risk factors are associated with CIP,[@b3-cpn-14-109],[@b12-cpn-14-109],[@b13-cpn-14-109] including age at first use, amount of substance, route of administration, use of other substances, personal vulnerability, and comorbid psychiatric disorders.[@b12-cpn-14-109],[@b13-cpn-14-109] Interestingly, some studies of patients with chronic cocaine addiction also reported low levels of BDNF.[@b3-cpn-14-109] However, there is no consensus regarding the role of BDNF level on cocaine use relapse.[@b14-cpn-14-109] There are few studies of the relationship between BDNF and CIP. To the best of our knowledge, only one study investigated patients with CIP and their BDNF levels. That study concluded that BDNF could play a role in psychotic symptoms in cocaine users because BDNF levels did not rise after withdrawal in patients with CIP compared with patients without a history of CIP.[@b5-cpn-14-109] This conclusion was reached following an observed correlation between a decreased BDNF level and CIP, which is similar to findings in patients with schizophrenia and other psychosis.[@b5-cpn-14-109] In this context, BDNF and other biological markers might be useful in identifying patients with a vulnerability for CIP and may also be a prognostic factor.[@b5-cpn-14-109]

Not only do neuropsychiatric diseases alter BDNF levels, but many other conditions such as diet, exercise, nicotine, and caffeine use alter BDNF levels as well. Some research suggests that diet and exercise could interact with BDNF expression.[@b15-cpn-14-109],[@b16-cpn-14-109] Caffeine increased BDNF expression in some animal models,[@b17-cpn-14-109],[@b18-cpn-14-109] as did nicotine[@b19-cpn-14-109]; however, not all investigations have come to this conclusion.[@b19-cpn-14-109]

We present two patients with cocaine dependence and CIP who were evaluated and included in an independent clinical trial conducted by the Psychiatry Department at the Vall d'Hebron University Hospital (Barcelona, Spain). These patients were hospitalized for cocaine detoxification, and serum BDNF levels were measured at the beginning of hospitalization as well as 12 days later. Both patients presented with psychotic symptoms during hospitalization, and were thus excluded from the clinical trial. Interestingly, BDNF levels further decreased during the psychotic episode compared with the levels found upon initial measurement.

CASE
====

The two patients were participants of a clinical trial that was conducted by the Psychiatry Department at the Vall d'Hebron University Hospital in which a combination of caffeine, biperiden, and placebo was evaluated as a treatment for cocaine dependence ([www.clinicaltrials.gov](www.clinicaltrials.gov) identifier: NCT00495092). That trial was approved by The Clinical Research Ethics Committee of the Vall d'Hebron University Hospital. All patients signed an informed consent form and agreed to be included in the study. Both individuals described earlier were excluded from that trial because they presented with psychotic symptoms during the study.

During their hospital stay, the patients were in a locked unit with no substance access and restrictions on visitation. They were detoxicated, and drug testing was performed during their hospitalization. The patients were seen every day by the psychiatrist who performed their initial clinical assessment and diagnosis (according the Diagnostic and Statistical Manual of Mental Disorders, fourth edition \[DSM-IV\] criteria).

As part of the original trial, they received caffeine or placebo; the general conditions were the same for all inpatients (e.g., diet, exercise). As per the protocol, two blood samples were collected from each patient in the original trial: one at the beginning and the other 12 days after the first sample was taken. No other samples were collected for BDNF assay. Serum BDNF was determined by sampling 8 ml of peripheral blood between 10:00 am and 12:00 am to avoid circadian interference. The samples were kept in anticoagulant-free tubes for 2 hours at 4°C. Serum BDNF was measured using a sandwich enzyme-linked immunosorbent (ELISA) system for quantitative protein measurement (Aushon Biosystems, Billerica, MA, USA).

Case 1
------

A 25-year-old male came to the detoxification unit to participate in the clinical trial. His last cocaine use was 24 hours prior to hospitalization. He presented with simple reference delusions with behavioral repercussion; furthermore, he had auditory hallucinations and some simple visual hallucinations. This psychotic pattern developed on day 5 after unit admission, and the episode duration was approximately 4 days. The patient did not have other mental nor neurological symptoms (e.g., his consciousness was never compromised, and no attention deficits were observed). This episode was investigated, and no metabolic etiology was established. A benzodiazepine was prescribed. On the first day of hospitalization, his initial BDNF level was measured: the BDNF level was low (70.94 ng/ml), and this level decreased further 12 days later (49.05 ng/ml).

The patient's psychiatric history included a major depressive (MD) episode, diagnosed 6 years prior, with total recovery. Cocaine and nicotine dependence were diagnosed before his hospitalization. He also had alcohol and benzodiazepine dependence, but had not recently used those substances. He sporadically used cannabis during his youth. No other substances were used. The patients did not have any other mental or medical antecedents, or antecedents of psychotic episodes.

Case 2
------

A 52-year-old male presented with a psychotic episode two days after hospitalization. This episode was characterized by suspiciousness, partially structured reference and prejudice delusions, and disorganized behavior. He had a short time and spatial disorientation at the beginning of this state, followed by normal attention and consciousness. Toxin screening, blood studies, and brain tomography were performed to rule out an organic cause for the psychosis. BDNF levels were measured on the first day of hospitalization (52.82 ng/ml) and again 12 days later (29.93 ng/ml) as per the protocol. The initial BDNF level was low; the second measurement was lower than the initial measurement and coincided with the patient's psychotic symptoms. The psychotic episode was treated with 200 mg/day quetiapine, and the psychotic symptoms were improved 10 days later.

No relevant antecedents were noted in his medical history (only surgical intervention for an anal abscess). However, the patient's psychiatric history included the previous diagnosis of a cluster A personality disorder (PD), not specified. He had a long toxicological history; he only had cocaine and nicotine dependence upon clinical hospitalization. He previously had heroin, cannabis, and alcohol dependence. There was no antecedent of psychotic episodes (with or without substance use).

DISCUSSION
==========

Here we reported two cases with cocaine dependence who had initial low serum BDNF levels upon hospitalization that decreased further in association with psychotic symptoms. Upon hospitalization, the patients were diagnosed with cocaine and tobacco dependence; no previous psychotic episodes (with or without substance use) were documented. It is important to point out that other causes of psychosis were ruled out in both patients (organic or pharmacological etiologies). It was important to consider the psychiatric history of both patients. In Case 1, the patient had a previous episode of MD, which must be considered when interpreting the BDNF level data. MD disorder has been correlated with low BDNF levels, which were then enhanced after antidepressant treatment.[@b20-cpn-14-109] In this patient, MD and psychotic episodes may have represented nervous system damage mediated by BDNF system alterations. In Case 2, a diagnosis of cluster A PD, not specified, was significant because evidence exists suggesting that PD could be a risk factor for psychosis conversion in at-risk patients.[@b21-cpn-14-109] There are few studies on the relationship between PD and BDNF. No studies exist on cluster A PD and BDNF; however, epigenetic changes in BDNF expression (DNA methylation) were investigated in patients with borderline PD,[@b22-cpn-14-109] and one study revealed a higher BDNF plasma level in patients with borderline PD.[@b22-cpn-14-109] Another study reported that platelet BDNF was decreased in males with borderline PD.[@b23-cpn-14-109]

The cases that we presented are in line with evidence suggesting that BDNF may be useful as a marker not only of psychotic episodes or schizophrenia[@b8-cpn-14-109],[@b9-cpn-14-109] but also of CIP[@b5-cpn-14-109] and addictive disorders.[@b3-cpn-14-109],[@b5-cpn-14-109] Our cases presented with an initial low level of BDNF similar to other reports of patients with cocaine dependence[@b3-cpn-14-109] and schizophrenia.[@b6-cpn-14-109],[@b8-cpn-14-109],[@b9-cpn-14-109],[@b24-cpn-14-109] Some researchers reported that the initial low levels increase until they normalize during cocaine withdrawal in patients without a history of CIP.[@b3-cpn-14-109],[@b5-cpn-14-109] Furthermore, in patients who use crack cocaine, BDNF levels increase after crack cocaine withdrawal.[@b25-cpn-14-109] We did not observe an increase in BDNF levels following cocaine withdrawal in our cases; conversely, we observed a marked reduction of those levels in our patients that coincided with psychotic episodes. BDNF reportedly decreased during the first psychotic episode,[@b10-cpn-14-109] and was associated with the duration of the first psychotic episode.[@b11-cpn-14-109] These data are interesting because few studies measured BDNF levels during a patient's first psychotic episode, and many studies were conducted in patients with chronic psychosis.[@b9-cpn-14-109] Employing BDNF as a biological marker could be useful in some aspects of psychosis, with the best use potentially being as a prognostic or disease activity biomarker for psychotic episodes.[@b1-cpn-14-109],[@b5-cpn-14-109],[@b8-cpn-14-109]--[@b11-cpn-14-109] Additionally, BDNF has been studied as a marker for different aspects of drug addictions (initiation, maintenance, abstinence, craving, risk factors) and also as a predictive factor for cocaine relapse.[@b14-cpn-14-109],[@b24-cpn-14-109] The interaction between BDNF and the dopaminergic system, particularly in midbrain dopaminergic neurons, could explain its relationship with drug reward and relapse.[@b1-cpn-14-109],[@b3-cpn-14-109],[@b24-cpn-14-109]

Finally, there are some limitations to extrapolating these cases. First, patients received placebo, caffeine, or biperiden during the original trial. In animal models, caffeine increased BDNF expression. However, the BDNF levels did not differ among the groups (including the placebo group) in the original trial.[@b3-cpn-14-109],[@b5-cpn-14-109] Both patients had nicotine dependence. Many animal and human studies found that nicotine increased BDNF expression and its levels[@b19-cpn-14-109]; however, some findings were inconsistent.[@b19-cpn-14-109] Specifically, one study showed that schizophrenic smokers had significantly increased BDNF levels and fewer positive symptoms than nonsmokers.[@b19-cpn-14-109] In our cases, BDNF levels were decreased, even with nicotine use. Both patients had the same exercise and diet conditions, which is important because diet and exercise can modify BDNF expression.[@b15-cpn-14-109],[@b16-cpn-14-109]

BDNF is an important neuropsychiatric biomarker that should be investigated further; its biological functions could explain its important correlation with several diseases. The correlation between BDNF and many aspects of psychotic episodes (duration, diagnosis, prognosis, etc.) could make it useful as a biological marker. The cases reported herein suggest a correlation between BDNF decrease and CIP. Although we only reported two cases, and other factors might be related to changes in BDNF levels, this information could be helpful in order to elucidate whether BDNF could be a biological marker for CIP. Future research should be conducted in this area, including specific trials that compared cocaine effects on BDNF levels in patients with CIP.
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